AskAt Inc. (AskAt) received a notice of allowance dated July 21, 2020 from the
Brazilian National Institute of Industrial Property (NIIP) in connection with
Application No. PI1014174-0, a use patent for AskAt’s EP4 antagonists in the
treatment of epithelial cancers.

Clinical Development of Grapiprant for Cancer Immunotherapy
Ikena Oncology (formally Kyn Therapeutics, a parent company of Arrys
Therapeutics, which licensed worldwide rights to AskAt’s EP4 antagonists except in
China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang
Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer
use in China), are currently conducting clinical studies of grapiprant (IK-007/RMX1002) in the U.S. and China, respectively.